Skip to main content
Article thumbnail
Location of Repository

Health economic evaluation in Japan: a case study of one aspect of health technology assessment

By Adam Oliver

Abstract

There is a burgeoning literature in health economic evaluation, with this form of analysis becoming increasingly influential at the health policy making level in a number of countries. However, a search of the literature reveals that in Japan, the world's second largest health care market, very little health economic evaluation has been undertaken. The main reason for the lack of interest in economic evaluation is that the fee-for-service and strict price regulation that characterises the system of health care financing in Japan is not conducive to this form of analysis. Moreover, the government and many researchers are satisfied that the current organisation of health care has given long life and low infant mortality at low cost. Even if it is accepted that low health care costs and good health prevail in Japan, slower economic growth rates, an ageing population and the development of new medical technologies will place increasing pressure on health care resources and will necessitate a more rational use of these resources. Good economic evaluation, by weighing benefits against costs, has an important role to play

Topics: HB Economic Theory
Year: 2003
DOI identifier: 10.1016/S0168-8510(02)00066-0
OAI identifier: oai:eprints.lse.ac.uk:160
Provided by: LSE Research Online
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://eprints.lse.ac.uk/160/1... (external link)
  • http://www.elsevier.com/locate... (external link)
  • http://eprints.lse.ac.uk/160/ (external link)
  • Suggested articles

    Citations

    1. ( 1996b) A case for the adoption of pharm a c o e c o n o m i c guidel i n e s in Japan.
    2. (1996). A case for the adoption of pharmacoeconomic guidelines in Japan. doi
    3. (1994). A critic al review of cancer scr eeni n g program s in Japan.
    4. (1994). A critical review of cancer screening programs in Japan. doi
    5. (1996). A review of phar m ac o e c o n o m i c studies in Japan (abstrac t C27). First Annual Interna t i o n a l Meetin g for the Associ a t i o n for Pharm a c o e c o n o m i c s and Outcom e s Resear c h , P h ilad e l p h i a ,
    6. (1996). A review of pharmacoeconomic studies doi
    7. (1995). An analysis of pharmacoeconomic studies in Japan.
    8. (1998). Applicability of pharmacoeconomic studies to policy decision in Japan. Iryo to
    9. (1995). Commonwe a lth of Australia
    10. (1994). Cultur e , confli c t , a nd cost: perspect i v e s on brain death
    11. (1994). Culture, conflict, and cost: perspectives on brain death in Japan. doi
    12. (1999). Effect of Japanes e govern m e n t policy on hospit a l pharm a c e u t i c a l profi t lev e l s .
    13. (1999). Effect of Japanese government policy on hospital pharmaceutical profit levels.
    14. (1995). Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: Including Submissions Involving Economic Analyses. Australian Government Printing Office,
    15. (1998). Ha m a shi m a
    16. (1997). Health c a r e tec hno l o g y assess m e n t and the challe n g e to pharm a c o e c o n o m i c s in Japan .
    17. (1998). Health econom i c s of care for patie n t s with cance r and intr a c t a b l e disea s e in Japan .
    18. (1998). Health economics of care for patients with cancer and intractable disease in Japan. doi
    19. (1988). Health tec hnology development in Japan.
    20. (1988). Health technology development in Japan.
    21. (1997). Healthcare technology assessment and the challenge to pharmacoeconomics in Japan. doi
    22. (1997). Japan’ s aging popula t i o n : implic a t i o n s for heal t h care.
    23. (1997). Japan’s aging population: implications for healthcare. doi
    24. (1995). Medical care in Japan. doi
    25. (1996). Nihon no Iryou. Chuokoronsha,
    26. (1994). Ontario Guidelines for Economic Analysis of Pharmaceutical Products. Ministry of Health,
    27. (1997). Public long-term care insurance in Japan. doi
    28. (1999). Sicknes s Funds Counci l
    29. (1999). Sickness Funds Council
    30. (1999). The cost-effectiveness of lifesaving interventions in Japan: do the variations found suggest irrational resource allocation?
    31. (1992). The economics of health care in Japan. doi
    32. (1994). The introducti o n and evaluat i o n of MRI
    33. (1994). The introduction and evaluation of MRI doi
    34. (1993). The Japanese health care syste m at the cross r o a d s : healt h care expend i t u r e s , techno l o g y util iz a t i o n and gaps in health care techno l o g y assess m e n t .
    35. (1993). The Japanese health care system at the crossroads: health care expenditures, technology utilization and gaps in health care technology assessment.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.